Literature DB >> 10955774

Telomerase activity and Bcl-2 expression in non-small cell lung cancer.

Y Ohmura1, M Aoe, A Andou, N Shimizu.   

Abstract

Bcl-2 and p53 are the most relevant proteins in apoptosis and tumor development. Telomerase functions in the maintenance of telomeres and is indispensable for immortalization. Bcl-2 was reported as a direct modulator of telomerase activity, and a correlation between p53 and telomerase activity was reported. The aim of this study was to determine the relationships between Bcl-2, p53, and telomerase activity in non-small cell lung cancer. Immunostaining for Bcl-2, p53, and Ki-67 was performed in 64 surgically resected non-small cell lung cancers, and a fluorescence-based telomeric repeat amplification protocol assay for semiquantitative analysis of telomerase activity was done. Twenty-eight (44%) and 33 (52%) cases showed positive staining for Bcl-2 and p53, respectively. Bcl-2 expression was associated with negative lymph node involvement (P = 0.0248). p53 expression was associated with tumor size (P = 0.0244), p stage (P = 0.0391), and proliferative activity (P = 0.0004). Telomerase activity was detected in 89.1% and was closely associated with aggressive clinicopathological features. Telomerase activity was higher in p53-positive tumors (P < 0.0001), but represented no correlation with Bcl-2 expression (P = 0.3239). Interestingly, when the cases were stratified by histological grade and the level of Ki-67 labeling index, Bcl-2 expression was more clearly associated with favorable clinicopathological features and lower telomerase activity only in low-grade tumors. In conclusion, p53 is closely associated with telomerase activity. In low-grade tumors, Bcl-2 is inversely correlated to telomerase activity. Our results suggest that the biological role of the Bcl-2 protein alters according to tumor aggressiveness, thereby cofunctioning with telomerase against genetic instability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10955774

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

1.  Prognostic significance of telomerase activity and some tumor markers in non-small cell lung cancer.

Authors:  Maha Hashim; Magda Sayed; Nervana Samy; Salah Elshazly
Journal:  Med Oncol       Date:  2010-02-10       Impact factor: 3.064

2.  Fumagillin treatment of hepatocellular carcinoma in rats: an in vivo study of antiangiogenesis.

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Wen-Juei Jeng; Chi-Juei Jeng; Yi-Ching Wang; Shu-Ling Gu; Shin-Yun Tseng; Chien-Ming Chu; Chia-Hui Lin; Kuo-Ming Chang
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

3.  Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients.

Authors:  Giuseppe Pelosi; Elisabetta Schianchi; Patrizia Dell'orto; Giulia Veronesi; Lorenzo Spaggiari; Felice Pasini; Gabriella Sozzi; Elisabeth Brambilla; Claudia Griso; Giuseppe Viale
Journal:  Virchows Arch       Date:  2005-09-29       Impact factor: 4.064

4.  Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases.

Authors:  Manfred Volm; Reet Koomägi; Jürgen Mattern; Thomas Efferth
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

5.  Quantification of alternative splicing variants of human telomerase reverse transcriptase and correlations with telomerase activity in lung cancer.

Authors:  Yan Liu; Bing-quan Wu; Hao-hao Zhong; Xin-xia Tian; Wei-gang Fang
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

6.  Multifunctional role of Bcl-2 in malignant transformation and tumorigenesis of Cr(VI)-transformed lung cells.

Authors:  Djordje Medan; Sudjit Luanpitpong; Neelam Azad; Liying Wang; Bing-Hua Jiang; Mary E Davis; John B Barnett; Lan Guo; Yon Rojanasakul
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

7.  The tetramethoxyflavone zapotin selectively activates protein kinase C epsilon, leading to its down-modulation accompanied by Bcl-2, c-Jun and c-Fos decrease.

Authors:  Ewa Toton; Natalia Lisiak; Blazej Rubis; Jaromir Budzianowski; Peter Gruber; Johann Hofmann; Maria Rybczynska
Journal:  Eur J Pharmacol       Date:  2012-02-21       Impact factor: 4.432

8.  Comparison between Platinum-Azidothymidine and Azidothymidine Effects on Bcl-2 and Telomerase Gene Expression in Rats with Hepatocellular Carcinoma.

Authors:  Abdolreza Sabokrouh; Asad Vaisi-Raygani; Mohammad Taghi Goodarzi; Shohreh Khatami; Massoud Taghizadeh-Jahed; Nahid Shahabadi; Niknam Lakpour; Yadollah Shakiba
Journal:  Avicenna J Med Biotechnol       Date:  2015 Apr-Jun

9.  Effects of treatment with platinum azidothymidine and azidothymidine on telomerase activity and bcl-2 concentration in hepatocellular carcinoma- induced rats.

Authors:  Abdolreza Sabokrouh; Mohammad Taghi Goodarzi; Asad Vaisi-Raygani; Shohreh Khatami; Masoud Taghizadeh-Jahed
Journal:  Avicenna J Med Biotechnol       Date:  2014-10

10.  Immunohistochemical analysis of B-cell lymphoma -2 in pleomorphic adenoma and mucoepidermoid carcinoma.

Authors:  Saede Atarbashi; Maryam Elahi; Mehdi Khani; Vahid Rakhshan
Journal:  Dent Res J (Isfahan)       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.